The XIENCE Alpine coronary stent system may be used by interventional cardiologists to treat a blockage and open the artery. A stent implant procedure is known as percutaneous coronary intervention (PCI).

XIENCE, which is also described as a drug-eluting stent (DES) or more specifically an everolimus-eluting stent (EES), is a leading DES because of its considerable safety data. XIENCE Alpine is engineered for complex intervention.

Precision in Stent Placement
MULTI-LINK design, with 100% accurate mid-marker to mid-marker stent placement, offers precise deployment

True Center Tip
Flexible tip design with co-axial positioning system (CPS) offers peak performance in complex lesions

Higher Performance Catheter
Catheter is engineered to optimize strength, flexibility and pushability

• Zero-transition distal shaft
• Proprietary skive design
• Robust hypotube with optimized thickness
• Specially formulated outer member

Durable Balloon with Flat Compliance
Thin, dual-layer balloon enables high pressure deployment while maintaining flexibility and strength.

The XIENCE fluoropolymer coating, unlike other polymers, interacts with blood proteins to reduce thrombus formation (through thromboresistance) in a process termed fluoropassivation.

XIENCE ALPINE SAFETY

IMPLANTED MORE THAN ANY OTHER DRUG-ELUTING STENT

XIENCE, the world’s leading drug-eluting stent (DES), is widely considered by industry experts in the field of cardiology to be the gold standard in drug-eluting metallic stent therapy.

EVIDENCE OF LOW STENT THROMBOSIS

After receiving a DES, patients need to take blood thinners—to prevent blood clot formation (stent thrombosis) which could potentially lead to a heart attack.

One indicator of XIENCE safety is apparent in a meta-analysis, which examined data from patients across 49 high-quality randomized controlled trials. The meta-analysis compared the safety between XIENCE and other drug-eluting stents, as well as between XIENCE and bare metal stents.

The results are illustrated below, with all of the findings confirming statistically significant lower rates of stent thrombosis with the XIENCE everolimus-eluting stent.

XIENCE: Significantly Lower Definite Stent Thrombosis in Large-Scale Meta-Analyses

IN-STENT THROMBOSIS RATES: XIENCE VS. OTHER DES

Compared to other drug-eluting stents (DES), XIENCE—with stent thrombosis (ST) rates of 0.0% and 0.1%—outperforms these other DES at 30 days:

MORE DATA ON XIENCE SAFETY

In a meta-analysis of all-comer complex patients that compared XIENCE everolimus-eluting stent to bare metal stents (BMS),** XIENCE was shown to save lives and help reduce heart attack risk.

Analyses reveal that XIENCE demonstrates the most thromboresistance when compared with several other types of bioabsorbable polymer drug-eluting stents.

The XIENCE fluoropolymer coating, unlike other polymers, interacts with blood proteins to reduce thrombus formation (through thromboresistance) in a process termed fluoropassivation.

Least Thrombus Area with XIENCE vs. BP-DES

In addition, XIENCE Alpine has been shown to be less thrombogenic compared to the Resolute Onyx stent, which employs a different polymer.

 Red areas indicate thrombus formation.

XIENCE is the world's leading drug-eluting stent. Its success is due to interventional cardiologists’ ability to effectively treat a broad range of patients—from simple to complex lesions, and from lower risk individuals to higher risk patients like those with diabetes or chronic total occlusion.

The XIENCE stent’s quality and performance are attributable to these features:

• It has a flexible and conformable design based on the proven MULTI-LINK design platform
• There is no touching or overlapping of struts when crimped
• There is minimal stent shortening when deployed
• It uses a catheter optimized for strength, flexibility and pushability
• It is engineered for complex cases
• It has excellent apposition and complete expansion
• It is manufactured from L-605 cobalt chromium (CoCr) alloy
• It is an everolimus-eluting stent (EES)